Glaukos Company (NYSE: GKOS), an ophthalmic medical know-how and pharmaceutical firm centered on novel therapies for the therapy of glaucoma, corneal problems and retinal ailments, at this time introduced the appointment of Denice Torres and Dr. Leana Wen to its Board of Administrators, efficient at this time. With the addition of those two administrators, Glaukos’ Board of Administrators can be comprised of 9 administrators, eight of whom are impartial.
“We’re delighted and honored to welcome these extremely completed professionals to the Glaukos Board. Every of those extraordinary ladies brings a wealth of related expertise, perspective, management and knowledge that can drastically improve our Board and be invaluable to our rising international group,” stated Thomas Burns, Glaukos president and chief government officer. “With greater than 25 years of administration expertise in prescription drugs, medical gadgets and client healthcare, Denice is a extremely completed government who has led important, profitable enterprise transformations. As a training emergency doctor and former Baltimore Well being Commissioner, Leana is a sought-after and trusted professional on a variety of well being coverage and public well being points. I imagine each ladies will play integral roles in Glaukos’ future and look ahead to their insights, steerage and counsel as we advance our mission to remodel the therapy of continual eye illness for the good thing about sufferers worldwide.”
Ms. Torres is presently chief government officer of The Ignited Firm, a Pennsylvania-based consulting agency she based in 2017. From 2005 to 2017, she served in varied senior management roles at Johnson & Johnson (J&J). From 2015 to 2017, she was chief technique and transformation officer for J&J’s international medical gadget enterprise, a $25 billion enterprise with greater than 50,000 staff. From 2011 to 2015, she was president of J&J McNeil Client Healthcare, the place she led the restoration of OTC manufacturers, together with the enduring Tylenol portfolio, by reworking enterprise operations, manufacturing, high quality programs and commercialization approaches, and creating excessive ranges of worker engagement throughout all features of the enterprise. From 2009 to 2011, she served as president of J&J Janssen Prescription drugs, Neuroscience. Ms. Torres was the only real recipient of the distinguished J&J HONOR award in 2016 for her work in range and inclusion, and he or she was named the 2015 Lady of the 12 months by the Healthcare Businesswomen’s Affiliation. Earlier than becoming a member of J&J, Ms. Torres constructed a profitable, 14-year profession at Eli Lilly and Firm, the place she centered on advertising and marketing and enterprise unit administration. In 2020, Ms. Torres joined the boards of venture-backed Nationwide Resilience, in addition to public firms Karuna Therapeutics and Bluebird Bio. She can also be the founding father of The Mentoring Place, a nonprofit group providing free government mentoring to assist ladies obtain their careers targets. Ms. Torres holds a B.S. in Psychology from Ball State College, a J.D. from Indiana College and an MBA from the College of Michigan. She is a member of the Michigan Bar Affiliation.
Dr. Wen is an emergency doctor and visiting professor of well being coverage and administration on the George Washington College College of Public Well being. She can also be a contributing columnist for The Washington Submit, writing on well being coverage and public well being, and an on-air commentator for CNN as a medical analyst. From 2015 to 2018, she was the well being commissioner for town of Baltimore, the place she led the nation’s oldest repeatedly working well being division to fight the opioid epidemic and enhance maternal and baby well being. From 2013 to 2015, Dr. Wen served as director of patient-centered care analysis within the division of emergency drugs at George Washington College, and authored a critically-acclaimed e-book on affected person advocacy. She has intensive expertise on boards in nonprofit and governmental sectors and with venture-backed well being innovation firms, and is presently on the board of the Bipartisan Coverage Heart and the Baltimore Group Basis, and the advisory board of the Behavioral Well being Group. She has additionally been a world well being fellow on the World Well being Group, a guide with the China Medical Board, the president of Deliberate Parenthood and a nonresident senior fellow on the Brookings Establishment. Dr. Wen’s work has been acknowledged by quite a few skilled organizations, together with as considered one of Trendy Healthcare’s High 50 Doctor-Executives, and, in 2019, she was named considered one of TIME journal’s 100 Most Influential Folks. She holds a B.S. from California State College, Los Angeles, an M.D. from Washington College College of Drugs and two M.Sc.s from the College of Oxford, the place she was a Rhodes Scholar. She accomplished her residency coaching at Brigham & Ladies’s Hospital and Massachusetts Basic Hospital, the place she was a medical fellow at Harvard Medical College.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical know-how and pharmaceutical firm centered on novel therapies for the therapy of glaucoma, corneal problems and retinal ailments. The corporate pioneered Micro-Invasive Glaucoma Surgical procedure, or MIGS, to revolutionize the standard glaucoma therapy and administration paradigm. Glaukos launched the iStent®, its first MIGS gadget, in the US in 2012, its next-generation iStent inject® gadget in the US in 2018, and most lately, the iStent inject W gadget in 2020. In corneal well being, Glaukos’ proprietary suite of single-use, bio-activated prescription drugs are designed to strengthen, stabilize and reshape the cornea by means of a course of referred to as corneal collagen cross-linking to deal with corneal ectatic problems and proper refractive situations. Glaukos is leveraging its platform know-how to construct a complete and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal well being and retinal illness.
View supply model on businesswire.com: https://www.businesswire.com/news/home/20210301005790/en/
Contacts
Media Contact:
Cassandra Dump
(619) 971-1887
Cassy@pascalecommunications.com
Investor Contact:
Chris Lewis
Director, Investor Relations & Company Technique & Improvement
(949) 481-0510
clewis@glaukos.com
